J&J Sees New MOAs For Refractory Populations As Anti-Depressant For Neuro Sales
This article was originally published in The Pink Sheet Daily
J&J’s five key therapeutic areas appear to be operating on all cylinders, based on presentations at the company’s annual analyst meeting. In neuroscience, already one of its core fields, it is expanding its anti-psychotic and mood disorders franchise to focus on difficult-to-treat patients, as well re-doubling efforts in challenging diseases like Alzheimer’s disease.
You may also be interested in...
Otsuka and Lundbeck’s newly approved long-acting antipsychotic Abilify Maintena enters a sub-sector of the anti-psychotic market dominated by Johnson & Johnson for the last decade, but the new competitor may be able to gain ground by helping to grow the patient population.
As many observers expected, top-line results from a Phase III study show bapineuzumab doesn’t work in carriers of the ApoE4 gene, who are at highest risk for Alzheimer’s disease. An interim analysis of another Phase III study in carriers will now be “expedited,” and other studies of non-carriers will keep going, Pfizer says.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.